Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics, Inc. (TVTX) announced a planned leadership transition in which Eric Dube, Ph.D., will step down as President, Chief Executive Officer and Board member effective December 1, 2026, then serve as Executive Advisor through February 15, 2027 and as a consultant for up to 18 months. Bradley L. Campbell, formerly President and CEO of Amicus Therapeutics, will become President, CEO and a Board member as of the same date under an employment agreement that includes a $1,000,000 annual base salary, a target bonus of 85% of base salary, and initial equity awards valued at about $16.5 million in stock options and time-based RSUs, plus a further $3.75 million performance-based RSU grant expected in early 2027. Both Dr. Dube’s transition package and Mr. Campbell’s agreement include detailed vesting, consulting and severance protections, with enhanced equity acceleration and cash severance if a qualifying termination occurs around a Change in Control.
Travere Therapeutics, Inc. (TVTX) reported that its Chief Research Officer, William E. Rote, exercised employee stock options for a total of 191,500 shares of common stock on September 15-16, 2026, at exercise prices including $15.46, $17.96, $25.25 and $26.88 per share. Over the same two days he sold an aggregate of 209,048 shares of common stock in open-market transactions at weighted average prices generally in the low-to-mid $60s per share. The sales were made pursuant to a written trading plan adopted on June 16, 2026, that meets the requirements of Rule 10b5-1(c), and the stock options exercised were reported as fully vested and exercisable.
Travere Therapeutics, Inc. (TVTX) reported that EVP and Chief Commercial Officer Peter Heerma exercised employee stock options and sold shares of common stock over September 15–17, 2026. He exercised 258,189 options at strike prices between $8.93 and $26.88 per share and sold 283,189 shares of common stock in market transactions pursuant to a Rule 10b5-1(c) trading plan adopted on June 16, 2026.
Travere Therapeutics, Inc. (TVTX) executive Jula Inrig, EVP, Head of R&D & CMO, reported an option exercise and related share sales. On September 15, 2026, she exercised 32,395 employee stock options at $8.93 per share, receiving the same number of common shares, and subsequently sold 44,674 shares of common stock in a series of brokerage or private transactions at prices around the low-to-mid $60s per share. Following the option exercise, 43,605 options under that grant remain directly held and are scheduled to expire on January 31, 2034. The reported sales were made under a pre-arranged Rule 10b5-1(c) trading plan adopted on June 16, 2026.
Travere Therapeutics, Inc. (TVTX) reported that its Chief Legal Officer and General Counsel, Elizabeth E. Reed, exercised 37,500 stock options for common shares at an exercise price of $15.46 per share on September 15, 2026, then sold 37,500 common shares in multiple open-market transactions the same day. The option was fully vested and exercisable, and the sales were made pursuant to a written trading plan adopted on June 16, 2026 that meets the requirements of Rule 10b5-1(c).
Travere Therapeutics, Inc. (TVTX) reported that Chief Executive Officer and director Eric M. Dube exercised employee stock options for a total of 400,000 shares of common stock at an exercise price of $23.34 per share on September 15–17, 2026, and sold 400,000 shares of common stock in open-market transactions on the same dates. The sales were made under a written trading plan adopted on June 16, 2026, that meets Rule 10b5-1(c) requirements, and the options exercised were fully vested and exercisable.
Travere Therapeutics, Inc. (TVTX) reports that its chief financial officer, Christopher R. Cline, exercised employee stock options for 20,000 shares of common stock at an exercise price of $17.44 per share on September 15, 2026, and the corresponding option position was reduced to zero. On the same date, he sold an aggregate of 50,508 shares of common stock in multiple open-market transactions at weighted average prices between approximately $62.00 and $65.31 per share. The sales were made pursuant to a Rule 10b5-1(c) trading plan adopted on June 16, 2026.
Travere Therapeutics, Inc. (TVTX) reported that Sandra Calvin, its SVP, Chief Accounting Officer, exercised employee stock options for a total of 5,375 shares of common stock on September 15, 2026 at strike prices of $27.50, $22.40, and $20.46 per share, and on the same date sold 5,375 shares of common stock in multiple transactions at weighted average prices between about $62.14 and $63.66. The sales were made pursuant to a Rule 10b5-1(c) trading plan adopted on June 16, 2026.
Travere Therapeutics, Inc. (TVTX) is the issuer for a planned resale of common stock reported by Eric Dube under Rule 144. The notice covers up to 108,493 shares of common stock to be sold through Morgan Stanley Smith Barney LLC, based on an aggregate market value of $6,887,135.64 and referencing 94,261,082 shares outstanding on September 17, 2026.
The shares to be sold are tied to an exercise of stock options on September 17, 2026, for cash. The filing also lists prior 10b5-1 sales of Travere common stock for Eric Dube over the past three months.
Travere Therapeutics, Inc. (TVTX) insider Peter Heerma, an officer, filed a notice of proposed sale of common stock under Rule 144. The notice lists a planned sale of 8,282 shares of common stock on September 17, 2026, following option exercises for cash with the issuer.
The filing also lists prior Rule 10b5-1 plan sales of Travere Therapeutics common stock during the preceding three months, reflecting significant recent disposition activity by the same insider.